Article
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2017
Khozin Sean, Weinstock Chana, Blumenthal Gideon M, Cheng Joyce, He Kun, Zhuang Luning, Zhao Hong, Charlab Rosane, Fan Ingrid, Keegan Patricia, Pazdur Richard
Abstract excerpt
On November 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer, as detected by an FDA-approved test, with progression on or after EGFR tyrosine kinase inhibitor therapy. Approval was based on durable tumor response rates in two single-arm,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.